Abstract:INTRODUCTION AND OBJECTIVES: AKR1C3, as a crucial steroidogenic enzyme, facilitated intratumoral androgen biosynthesis and androgen receptor (AR) reactivation in the development of castration-resistant prostate cancer. Also, amount of data have shown that AKR1C3 expression was significantly elevated in clinical metastatic prostate cancer (PCa) specimens, indicating an alternative role of AKR1C3 in PCa metastasis. Epithelial-mesenchymal transition (EMT) has been recognized to play pivotal roles in promoting carcinoma invasion and metastasis; however, the roles of AKR1C3 in EMT and PCa metastasis have not been fully elucidated. METHODS: C4-2, 22RV1-T and PC-3 cells with higher AKR1C3 expression were selected and treated with several specific AKR1C3 shRNAs or small molecule inhibitor, and the cell migration and invasion abilities were detected by wound healing assay and Transwell assay. The expression of EMT markers (i.e., E-cadherin and vimentin) and the related transcription factors (i.e., Snail, Slug, ZEB1 and Twist1) was examined by Western blot or quantitative PCR assays, and the phosphorylation of AKT or ERK was detected by Western blot. Also, the expression of vimentin, ZEB1 and p-ERK (T202/Y204) was detected by immunohistochemical staining in PC-3 xenograft tissues after AKR1C3 inhibitor treatment. The correlation between AKR1C3 and EMT markers (including EMT-related transcription factors) expression in clinical specimens from tissue microarray or TCGA database was analyzed. RESULTS: AKR1C3 was overexpressed in more aggressive PCa cell lines regardless of the AR status. Knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could significantly suppressed cell migration and invasion abilities in vitro. Also, knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could increase E-cadherin expression but decrease vimentin expression, in which the phosphorylation of ERK and the transcription factor ZEB1 expression were specifically downregulated. In consistency, inhibition of AKR1C3 activity by inhibitor treatment could decrease the expression of vimentin, ZEB1 and p-ERK (T202/Y204) in xenograft tissues in vivo. Moreover, there was a significant correlation between AKR1C3 and EMT markers (i.e., E-cadherin, vimentin and ZEB1) in human PCa specimens. CONCLUSIONS: AKR1C3 is a novel EMT regulator in PCa metastasis through activation of MAPK/ERK signaling and upregulation of ZEB1 expression.

Prkar2b Promotes Prostate Cancer Metastasis By Activating Wnt/-Catenin And Inducing Epithelial-Mesenchymal Transition

CRABP2 Promotes Cell Migration and Invasion by Activating PI3K/AKT and MAPK Signalling Pathways Via Upregulating LAMB3 in Prostate Cancer

PRKAR2B Plays an Oncogenic Role in the Castration-Resistant Prostate Cancer

Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis

CRABP2 promotes cell migration and invasion by activating PI3K/AKT and MAPK signaling pathways via up-regulating LAMB3 in prostate cancer

Transcriptional Regulation of PRKAR2B by Mir-200B-3p/200c-3p and XBP1 in Human Prostate Cancer.

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Human Kallikrein 2 (KLK2) Promotes Prostate Cancer Cell Growth Via Function As a Modulator to Promote the ARA70-enhanced Androgen Receptor Transactivation.

Lung Cancer Metastasis-Related Protein 1 Promotes the Transferring from Advanced Metastatic Prostate Cancer to Castration-Resistant Prostate Cancer by Activating the Glucocorticoid Receptor Α Signal Pathway.

MP62-19 AKR1C3 OVEREXPRESSION IN PROSTATE CANCER PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION AND METASTASIS VIA ACTIVATION OF MAPK/ERK SIGNALING AND UPREGULATION OF ZEB1

Cathepsin K regulates the tumor growth and metastasis by IL-17/CTSK/EMT axis and mediates M2 macrophage polarization in castration-resistant prostate cancer

Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy

Lipocalin 2 Over-Expression Facilitates Progress of Castration-Resistant Prostate Cancer Via Improving Androgen Receptor Transcriptional Activity

ATM‑JAK‑PD‑L1 Signaling Pathway Inhibition Decreases EMT and Metastasis of Androgen‑independent Prostate Cancer.

The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.

The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling

SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer Via PI3K/AKT and ERK1/2 Pathways

Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone

BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance

Ccr2 Expression Correlates With Prostate Cancer Progression

LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production